This inventor holds 2 USPTO granted patents. Top assignees: Seoul National University, Snu Rdb Foundation. Active years: 2015-2023.
Company Filing History:
Years Active: 2015-2023
Title: In-Ah Kim: Innovating Cancer Treatment through Patents
Introduction
In-Ah Kim, a prominent inventor based in Seongnam-si, South Korea, has made significant strides in the field of oncology. With two patents to his name, he is focused on advancing treatments for metastatic triple negative breast cancer. His research and innovations showcase the intersection of pharmaceutical compositions and radiotherapy methods to improve patient outcomes.
Latest Patents
In-Ah Kim's latest patents reflect his commitment to enhancing cancer treatment methodologies. One of his notable inventions is the "Method of treating metastatic triple negative breast cancer with radiotherapy combined with phosphatidyl inositol-3 kinase delta/gamma inhibitors and anti-PD-1 antibodies." This invention provides a pharmaceutical composition and treatment method that combines PD-1 blockade and PI3K inhibitors along with radiotherapy. The combination demonstrates outstanding results in inhibiting tumors and enhancing immunity, showcasing superior efficacy compared to traditional therapies.
Another groundbreaking patent is the "Modulation of radiation response using microRNA." This technology focuses on increasing sensitivity to radiotherapy through microRNA. It involves a radiosensitizer composition that includes microRNA-26b, microRNA-203, and microRNA-200c, along with anticancer supplements. The methodology aims to enhance the sensitivity of cancer cells to radiotherapy, further contributing to the fight against cancer.
Career Highlights
In-Ah Kim has worked with notable organizations, including the Snur & Db Foundation and the Seoul National University R&D Foundation. His contributions have advanced research initiatives focused on innovative cancer treatments, reinforcing his status as an influential figure in the scientific community.
Collaborations
Collaboration is key to innovation, and In-Ah Kim has worked alongside talented colleagues such as Bong-Jun Cho and Eun Jung Choi. These partnerships facilitate a sharing of ideas and expertise, enabling more comprehensive approaches to tackling complex health issues like cancer.
Conclusion
In-Ah Kim's pioneering work in the realm of cancer treatment exemplifies how innovative thinking and collaborative efforts can lead to meaningful advancements. His patents not only highlight his exceptional inventiveness but also represent hope for improved therapeutic options for patients battling metastatic triple negative breast cancer. As the field continues to evolve, In-Ah Kim remains at the forefront of developing effective cancer treatments through innovation.